Drug Profile
Istradefylline - Kyowa Kirin
Alternative Names: Istradefylline - Kyowa Hakko Kirin; KW-6002; NOURIANZ; NouriastLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Developer Kyowa Kirin
- Class Antidepressants; Antiparkinsonians; Neuroprotectants; Small molecules; Xanthines
- Mechanism of Action Adenosine A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Parkinson's disease
- Discontinued Major depressive disorder; Restless legs syndrome; Substance-related disorders
Most Recent Events
- 25 Jul 2021 Committee for Medicinal Products for Human Use (CHMP) adopts a negative opinion for istradefylline for Parkinson’s disease
- 25 Apr 2020 Efficacy and adverse events data from a phase III trial in Parkinson's disease presented at the 72nd Annual Meeting of the American Academy of Neurology (AAN-2020)
- 31 Dec 2019 Preregistration for Parkinson's disease in European Union (PO) (Kyowa Kirin pipeline, December 2019)